Septerna, Inc. (SEPN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$36.75-0.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Septerna grows revenue from its Novo Nordisk deal to $26.5 million in Q1 2026. The company plans to fund operations through 2029. It advances its drug SEP-631 into Phase 2 trials. Recent earnings beats show improving execution.
Septerna is still losing money and revenue may decline after 2026. Litigation and trial risks could delay drug development. Cash may run short before 2029. Earnings misses in 2025 show challenges.
The price is about 6% below our fair value near $38. Analysts expect about 6% revenue decline next year. Our fair value is 27% below the Street median, reflecting caution.
Breaks if: Cash runway falls short of supporting operations into 2029
Breaks if: Revenue from Novo Nordisk falls below $21.5 million in Q1 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment focused on advancing clinical developments. The current thesis state reflects a recent shift from robust to fragile, indicating increased uncertainty around future performance.
The market seems to be pricing in a low expectations gap, with a durable premium compared to peers. This suggests that while the stock may not be overly fragile, investors are cautious about its future potential.
Fundamentals are likely to remain under pressure due to weak recent performance and elevated risks in the industry. However, management's stable focus on advancing clinical trials may provide some support.
The thesis hinges on management's ability to maintain guidance and advance clinical trials without significant setbacks. Additionally, the performance of sector bellwethers and broader economic indicators will play a crucial role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates a weakened reason to own the stock. Additionally, significant stock sales by key investors raise concerns about confidence in the company's future.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Drive revenue growth through collaboration with Novo Nordisk on oral small molecule medicines for cardiometabolic diseases.
Stated in 3 of last 3 quarters. Revenue from the Novo Nordisk collaboration increased from $24.1M in 2025-Q4 to $26.7M in 2026-Q2, showing growth consistent with management's stated priority. This reflects ongoing milestone and research service revenue contributions.
“Revenue from Novo Nordisk collaboration was $26.7 million for the quarter.”
“Revenue from Novo Nordisk collaboration was $26.5 million for the quarter.”
“Revenue was $24.1 million for the fourth quarter of 2025.”
Breaks if: SEP-631 development stalls before or during Phase 2 trials
Over the next 1 to 3 years, SEPN's outlook will depend on its clinical development progress and external market conditions. Not investment advice.